SBRT/SABR (Stereotactic Body Radiotherapy) for Cancerous Tumours
Stereotactic Radiosurgery
Stereotactic Radiosurgery (SRS) for Brain and Spine Tumours
Total Body Irradiation
Qualifications
MBBS - Siddhartha Medical College - 2001 - Vijaywada Verified
MD - Radiotherapy - Nizam Institute of Medical Sciences - 2006 - Hyderabad Verified
DNB - Radiotherapy - National Board of Examination - 2011 Verified
Experiences
Registrar Yashoda Hospital - 2007 - 2008
Consultant Radiation Oncologist Yashoda Hospitals - Somajiguda - 2008 - Currently Working
Registrations
46981 Andhra Pradesh Medical Council 2002 Verified
Memberships
Indian Medical Association
European Society for Medical Oncology
Association of Radiation Oncologist of India
Paper Presentations
Principal Investigator Trial Number : 1200:131 Trial Title - Lux -Head and Neck 2 : Randomised, Double Blind, Placebo -Controlled, Phase Iii Study To Evaluate The Efficacy And Safety Of Afatinib As Adjuvant Therapy After Chemo -Radiotherapy In Primary Unresected Patients With Stage Iii, Iva, Or Ivb Loco - Regionally Advanced Head And Neck Squamous Cell Carcinoma
Principal Investigator In Trial No 1200.161 - Trial Title - A Randomized- Open-Label- Phase Iii Study To Evaluate The Efficacy And Safety Of Oral Afatinib Versus Intravenous Methotrexate In Patients With Recurrent And/Or Metastatic Head And Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-Based Therapy
A Multicenter Phase Ii/Iii Study To Assess Radiation Induced Mucositis In Subjects With Locally Advanced Squamous Cell Carcinoma of The Head and Neck- Administered Cisplatin And Radiation With Or Without P276-00
Title Netu 08 - 18 : A Phase Iii Multicenter - Randomized - Double - Blind - Double - Dummy - A Ctive - Controlled - Parallel Group Study of The Efficacy And Safety of Oral Netupitant Administered In Combination With Palonosetron And Dexamethasone Compared To Oral Palonosetron And Dexamethasone For The Prevention of Nausea And Vomiting In Cancer Patients Receiving Moderately Emetogenic Chemotherapy
Palo10 - 01: Single Dose - Multicenter - Randomized - Double -Blind - Double - Dummy - Parallel Group Study To Assess The Efficacy And Safety of Oral Palonosetron 0.50 Mg Compared To I.V Palonosetron 0.25Mg Administered With Dexamthasone For The Prevention Of Chemotherapy - Induced Nausea And Vomiting In Cancer Patients Receiving Highly Emetogenic Cisplatin - Based Chemotherapy